FIGURE 3.
Overall survival (OS) at the interim OS analysis. Data cutoff was July 18, 2019. APP, atezolizumab plus cisplatin plus pemetrexed; NE, not evaluable; PP, cisplatin plus pemetrexed.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.